Takeda Pharmaceutical Company Limited (TAK)

Takeda Pharmaceutical Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	192,026	108,143	144,197	317,038	230,166
Depreciation & Amortization	721,127	761,396	728,002	664,400	583,151
Stock-Based Compensation	72,775	72,867	70,871	60,672	43,374
Other Adjustments	348,260	334,667	238,872	235,055	266,825
Change in Receivables	-70,166	-58,959	15,104	75,127	127,294
Changes in Inventories	-61,293	-34,973	-115,743	-79,155	-46,148
Changes in Accounts Payable	-3,150	-7,118	-9,895	-84,804	125,157
Changes in Accrued Expenses	13,576	45,166	-126,901	31,899	-58,090
Changes in Income Taxes Payable	-172,562	-150,413	-202,039	-185,966	-140,423
Changes in Other Operating Activities	839	-13,595	-26,124	-57,109	-8,199
Operating Cash Flow	1,041,430	1,057,180	716,344	977,156	1,123,110
Operating Cash Flow Growth	-1.49%	47.58%	-26.69%	-13.00%	11.10%
Capital Expenditures	-176,003	-200,795	-175,420	-140,657	-123,252
Sale of Property, Plant & Equipment	6,454	78	8,606	962	1,815
Purchases of Intangible Assets	-238,656	-178,830	-305,310	-493,032	-62,785
Purchases of Investments	-16,518	-98,540	-6,766	-10,151	-8,341
Proceeds from Sale of Investments	7,911	87,133	8,021	22,254	16,921
Payments for Business Acquisitions	-	-	-	-	-49,672
Proceeds from Business Divestments	33,325	20,556	19,959	7,958	28,196
Other Investing Activities	14,346	3,337	-12,951	5,564	-1,008
Investing Cash Flow	-369,141	-367,060	-463,862	-607,102	-198,125
Short-Term Debt Issued	-341,780	27,490	277,000	40,000	-2
Net Short-Term Debt Issued (Repaid)	-341,780	27,490	277,000	40,000	-2
Long-Term Debt Issued	586,060	1,024,460	100,000	75,000	249,334
Long-Term Debt Repaid	-200,432	-1,321,090	-320,901	-356,670	-810,115
Net Long-Term Debt Issued (Repaid)	385,628	-296,630	-220,901	-281,670	-560,781
Repurchase of Common Stock	-51,603	-51,860	-2,326	-26,929	-77,531
Net Common Stock Issued (Repurchased)	-51,603	-51,860	-2,326	-26,929	-77,531
Common Dividends Paid	-311,901	-302,498	-287,188	-279,416	-283,665
Other Financing Activities	-177,163	-127,925	-121,000	-161,134	-148,286
Financing Cash Flow	-496,820	-751,425	-354,416	-709,148	-1,070,270
Effect of Exchange Rate Changes on Cash and Cash Equivalents	34,472	-11,385	26,204	22,929	28,758
Net Cash Flow	175,469	-61,303	-101,934	-339,094	-145,285
Free Cash Flow	865,428	856,387	540,924	836,499	999,853
Free Cash Flow Growth	1.06%	58.32%	-35.34%	-16.34%	11.13%
FCF Margin	19.21%	18.69%	12.69%	20.77%	28.01%
Free Cash Flow Per Share	269.97	266.73	171.14	266.42	316.98
Levered Free Cash Flow	558,144	238,456	272,046	223,955	1,472
Unlevered Free Cash Flow	624,210	611,271	656,619	563,198	682,760

Updated May 13, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q